Nevertheless, this study gives significant insight into the answer to different responses to EBV-inducing autoimmunity among the population with equal level cross-reactive GlialCAM antibody, which facilitates accurate prediction of MS occurrence and development of novel therapy against MS in the future. This evidence concerns the gene HEPACAM and myeloid sarcoma.